Logo image of SYENS.BR

SYENSQO SA (SYENS.BR) Stock Fundamental Analysis

EBR:SYENS - Euronext Brussels - BE0974464977 - Common Stock - Currency: EUR

67  -1.22 (-1.79%)

Fundamental Rating

3

Taking everything into account, SYENS scores 3 out of 10 in our fundamental rating. SYENS was compared to 66 industry peers in the Chemicals industry. SYENS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SYENS has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

SYENS had positive earnings in the past year.
In the past year SYENS had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: SYENS reported negative net income in multiple years.
SYENS had a positive operating cash flow in each of the past 5 years.
SYENS.BR Yearly Net Income VS EBIT VS OCF VS FCFSYENS.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 500M -500M 1B -1B

1.2 Ratios

Looking at the Return On Assets, with a value of -0.89%, SYENS is doing worse than 60.61% of the companies in the same industry.
Looking at the Return On Equity, with a value of -1.50%, SYENS is doing worse than 60.61% of the companies in the same industry.
SYENS has a Return On Invested Capital of 2.53%. This is comparable to the rest of the industry: SYENS outperforms 50.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for SYENS is in line with the industry average of 6.53%.
The last Return On Invested Capital (2.53%) for SYENS is well below the 3 year average (8.47%), which needs to be investigated, but indicates that SYENS had better years and this may not be a problem.
Industry RankSector Rank
ROA -0.89%
ROE -1.5%
ROIC 2.53%
ROA(3y)2.81%
ROA(5y)0.13%
ROE(3y)7.26%
ROE(5y)-1.97%
ROIC(3y)8.47%
ROIC(5y)7.63%
SYENS.BR Yearly ROA, ROE, ROICSYENS.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -20 -40

1.3 Margins

SYENS has a Operating Margin (5.00%) which is comparable to the rest of the industry.
In the last couple of years the Operating Margin of SYENS has declined.
Looking at the Gross Margin, with a value of 31.61%, SYENS is in line with its industry, outperforming 48.48% of the companies in the same industry.
SYENS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 5%
PM (TTM) N/A
GM 31.61%
OM growth 3Y-4.48%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.24%
GM growth 5YN/A
SYENS.BR Yearly Profit, Operating, Gross MarginsSYENS.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 10 -10 20 -20 30

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), SYENS is creating some value.
Compared to 1 year ago, SYENS has less shares outstanding
SYENS has a better debt/assets ratio than last year.
SYENS.BR Yearly Shares OutstandingSYENS.BR Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
SYENS.BR Yearly Total Debt VS Total AssetsSYENS.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

SYENS has an Altman-Z score of 2.19. This is not the best score and indicates that SYENS is in the grey zone with still only limited risk for bankruptcy at the moment.
SYENS's Altman-Z score of 2.19 is in line compared to the rest of the industry. SYENS outperforms 53.03% of its industry peers.
SYENS has a debt to FCF ratio of 23.55. This is a negative value and a sign of low solvency as SYENS would need 23.55 years to pay back of all of its debts.
With a Debt to FCF ratio value of 23.55, SYENS perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
SYENS has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
SYENS's Debt to Equity ratio of 0.25 is fine compared to the rest of the industry. SYENS outperforms 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 23.55
Altman-Z 2.19
ROIC/WACC0.37
WACC6.85%
SYENS.BR Yearly LT Debt VS Equity VS FCFSYENS.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2B 4B 6B

2.3 Liquidity

A Current Ratio of 1.58 indicates that SYENS should not have too much problems paying its short term obligations.
SYENS has a Current ratio of 1.58. This is comparable to the rest of the industry: SYENS outperforms 43.94% of its industry peers.
A Quick Ratio of 0.96 indicates that SYENS may have some problems paying its short term obligations.
SYENS has a Quick ratio of 0.96. This is in the lower half of the industry: SYENS underperforms 63.64% of its industry peers.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 0.96
SYENS.BR Yearly Current Assets VS Current LiabilitesSYENS.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2

3. Growth

3.1 Past

SYENS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -102.63%.
The Revenue has decreased by -3.10% in the past year.
SYENS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.31% yearly.
EPS 1Y (TTM)-102.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.14%
Revenue 1Y (TTM)-3.1%
Revenue growth 3Y4.31%
Revenue growth 5YN/A
Sales Q2Q%-0.31%

3.2 Future

Based on estimates for the next years, SYENS will show a small growth in Earnings Per Share. The EPS will grow by 7.94% on average per year.
SYENS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.23% yearly.
EPS Next Y6.78%
EPS Next 2Y12%
EPS Next 3Y12.22%
EPS Next 5Y7.94%
Revenue Next Year1.22%
Revenue Next 2Y2.83%
Revenue Next 3Y3.48%
Revenue Next 5Y2.23%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SYENS.BR Yearly Revenue VS EstimatesSYENS.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B 8B
SYENS.BR Yearly EPS VS EstimatesSYENS.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2 4 6 8

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 14.11, which indicates a correct valuation of SYENS.
Based on the Price/Earnings ratio, SYENS is valued a bit cheaper than the industry average as 78.79% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.31, SYENS is valued a bit cheaper.
SYENS is valuated reasonably with a Price/Forward Earnings ratio of 10.14.
Based on the Price/Forward Earnings ratio, SYENS is valued cheaply inside the industry as 89.39% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of SYENS to the average of the S&P500 Index (22.13), we can say SYENS is valued rather cheaply.
Industry RankSector Rank
PE 14.11
Fwd PE 10.14
SYENS.BR Price Earnings VS Forward Price EarningsSYENS.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

SYENS's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. SYENS is cheaper than 77.27% of the companies in the same industry.
SYENS's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 79.46
EV/EBITDA 7.86
SYENS.BR Per share dataSYENS.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
SYENS's earnings are expected to grow with 12.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.08
PEG (5Y)N/A
EPS Next 2Y12%
EPS Next 3Y12.22%

1

5. Dividend

5.1 Amount

SYENS has a Yearly Dividend Yield of 1.62%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 2.93, SYENS has a dividend in line with its industry peers.
SYENS's Dividend Yield is slightly below the S&P500 average, which is at 2.39.
Industry RankSector Rank
Dividend Yield 1.62%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years1
SYENS.BR Yearly Dividends per shareSYENS.BR Yearly Dividends per shareYearly Dividends per share 2024 2025 0.5 1 1.5

5.3 Sustainability

The earnings of SYENS are negative and hence is the payout ratio. SYENS will probably not be able to sustain this dividend level.
DP-157.41%
EPS Next 2Y12%
EPS Next 3Y12.22%
SYENS.BR Yearly Income VS Free CF VS DividendSYENS.BR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2020 2021 2022 2023 2024 0 500M -500M -1B

SYENSQO SA

EBR:SYENS (6/13/2025, 7:00:00 PM)

67

-1.22 (-1.79%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)05-15 2025-05-15/bmo
Earnings (Next)07-31 2025-07-31
Inst Owners27.72%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap6.99B
Analysts79.29
Price Target84.58 (26.24%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.62%
Yearly Dividend1.63
Dividend Growth(5Y)N/A
DP-157.41%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.73%
Min EPS beat(2)-38.67%
Max EPS beat(2)-4.8%
EPS beat(4)0
Avg EPS beat(4)-15.85%
Min EPS beat(4)-38.67%
Max EPS beat(4)-4.8%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.74%
Min Revenue beat(2)-2.18%
Max Revenue beat(2)-1.3%
Revenue beat(4)0
Avg Revenue beat(4)-2.99%
Min Revenue beat(4)-4.61%
Max Revenue beat(4)-1.3%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.78%
PT rev (3m)-13.02%
EPS NQ rev (1m)-6.04%
EPS NQ rev (3m)-25.14%
EPS NY rev (1m)0%
EPS NY rev (3m)-12.43%
Revenue NQ rev (1m)-3.71%
Revenue NQ rev (3m)-3.77%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.65%
Valuation
Industry RankSector Rank
PE 14.11
Fwd PE 10.14
P/S 1.03
P/FCF 79.46
P/OCF 9.05
P/B 0.97
P/tB 2.28
EV/EBITDA 7.86
EPS(TTM)4.75
EY7.09%
EPS(NY)6.61
Fwd EY9.87%
FCF(TTM)0.84
FCFY1.26%
OCF(TTM)7.41
OCFY11.05%
SpS65.17
BVpS69.12
TBVpS29.33
PEG (NY)2.08
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.89%
ROE -1.5%
ROCE 3.38%
ROIC 2.53%
ROICexc 2.7%
ROICexgc 4.81%
OM 5%
PM (TTM) N/A
GM 31.61%
FCFM 1.29%
ROA(3y)2.81%
ROA(5y)0.13%
ROE(3y)7.26%
ROE(5y)-1.97%
ROIC(3y)8.47%
ROIC(5y)7.63%
ROICexc(3y)9.08%
ROICexc(5y)8.08%
ROICexgc(3y)19%
ROICexgc(5y)18.92%
ROCE(3y)11.29%
ROCE(5y)10.17%
ROICexcg growth 3Y-19.3%
ROICexcg growth 5YN/A
ROICexc growth 3Y-9.3%
ROICexc growth 5YN/A
OM growth 3Y-4.48%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.24%
GM growth 5YN/A
F-Score5
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 23.55
Debt/EBITDA 1.63
Cap/Depr 91.58%
Cap/Sales 10.07%
Interest Coverage 250
Cash Conversion 71.05%
Profit Quality N/A
Current Ratio 1.58
Quick Ratio 0.96
Altman-Z 2.19
F-Score5
WACC6.85%
ROIC/WACC0.37
Cap/Depr(3y)98.43%
Cap/Depr(5y)76.05%
Cap/Sales(3y)9.47%
Cap/Sales(5y)8.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-102.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.14%
EPS Next Y6.78%
EPS Next 2Y12%
EPS Next 3Y12.22%
EPS Next 5Y7.94%
Revenue 1Y (TTM)-3.1%
Revenue growth 3Y4.31%
Revenue growth 5YN/A
Sales Q2Q%-0.31%
Revenue Next Year1.22%
Revenue Next 2Y2.83%
Revenue Next 3Y3.48%
Revenue Next 5Y2.23%
EBIT growth 1Y-33.42%
EBIT growth 3Y-0.36%
EBIT growth 5YN/A
EBIT Next Year51.65%
EBIT Next 3Y21.42%
EBIT Next 5Y14%
FCF growth 1Y-48.94%
FCF growth 3Y-7.48%
FCF growth 5YN/A
OCF growth 1Y-34.04%
OCF growth 3Y7.55%
OCF growth 5YN/A